For the better part of a year, the story of AI physiotherapy in the NHS has been told almost entirely in the language of momentum. A Cambridge start-up, Flok Health, secured Class IIa medical device approval under EU regulations in October 2025, becoming the first AI system in Europe cleared to deliver a full care pathway, including diagnostic decisions, without a human clinician supervising each case. The clearance initially covered back pain and sciatica. In August 2026 it

For most of the last three years, the story of metabolic health has been told as a pharmaceutical story. Semaglutide and tirzepatide rewrote the economics of obesity, turned Novo Nordisk and Eli Lilly into two of the most valuable companies in the world, and pulled a once-marginal clinical category into the centre of health policy. In the first nine months of 2025 alone, Lilly's Mounjaro and Zepbound generated $39.5 billion in revenue, overtaking Keytruda as the world's best-